NCT04431804

Brief Summary

Invasive Aspergillosis (IA) has increasingly been recognized as an emerging disease of non-neutropenic patients and in patients admitted to the ICU, even in the absence of an apparent predisposing immune-deficiency, with incidence ranges from 0.3% to 5.8% with an overall mortality rate exceeding 80%.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
210

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 11, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

June 11, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 16, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2020

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2020

Completed
Last Updated

November 5, 2020

Status Verified

November 1, 2020

Enrollment Period

3 months

First QC Date

June 11, 2020

Last Update Submit

November 4, 2020

Conditions

Aspergillosis

Outcome Measures

Primary Outcomes (1)

  • fungicidal effect of silver nanoparticles on aspergillus fumigatus

    24 hours

Interventions

silver nanoparticleOTHER

fungicidal effect of silver nanoparticles on aspergillus isolates

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

intensive care patients

You may qualify if:

  • intensive care patients

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, 71111, Egypt

Location

MeSH Terms

Conditions

Aspergillosis

Condition Hierarchy (Ancestors)

MycosesBacterial Infections and MycosesInfections

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anaesthesia

Study Record Dates

First Submitted

June 11, 2020

First Posted

June 16, 2020

Study Start

June 11, 2020

Primary Completion

September 20, 2020

Study Completion

September 30, 2020

Last Updated

November 5, 2020

Record last verified: 2020-11

Locations

EG(1)